Tumor-associated microbiota in colorectal cancer with vascular tumor thrombus and neural invasion and association with clinical prognosis

Acta Biochim Biophys Sin (Shanghai). 2024 Mar 25;56(3):366-378. doi: 10.3724/abbs.2023255.

Abstract

Neural invasion (NI) and vascular tumor thrombus (VT) are associated with poor prognosis in patients with colorectal cancer (CRC). In this study, we apply 16S rRNA amplicon sequencing to tumor tissues and adjacent normal tissues in patients with CRC to determine the microbial differences. A discovery cohort, including 30 patients with NI, 23 with VT, and 35 with double-negative CRC tissue, is utilized. Then, we analyze the relationship between the specific bacterial taxa and indicators of different dimensions in separate cohorts. In the discovery cohort, the diversity and composition of the gut microbiome distinctly differ between the tumor and nontumor tissues in the NI and VT groups. A high abundance of Cupriavidus is found to be related to a short survival time of NI CRC, while Herbaspirillum is a potential microbial biomarker predicting the prognosis of patients with CRC with NI or VT. Moreover, the abundance of Cupriavidus or Herbaspirillum is associated with some clinical patient characteristics and prognosis, respectively. In conclusion, this study is the first to comprehensively elaborate the differences in the gut microbiota of patients with CRC with different invasion statuses and to prove the relationship between some gut microbiota and clinical patient characteristics.

Keywords: 16S rRNA; colorectal cancer; gut microbiota.

MeSH terms

  • Colorectal Neoplasms* / pathology
  • Humans
  • Microbiota*
  • RNA, Ribosomal, 16S / genetics
  • Thrombosis*
  • Vascular Neoplasms*

Substances

  • RNA, Ribosomal, 16S

Grants and funding

This work was supported by the grants from the Beijing Bethune Public Welfare Foundation (No. BJ GYQZHX2021006), the Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province (No. CXPJJH122006-1003), the National Key R&D Program of China (No. 2018YFC1313300), the National Natural Science Foundation of China (Nos. 82373050, 82203808 and 81472707), the Clinical Research Special Fund of Wu Jieping Medical Foundation (No. 320.6750.2023-19-7), and the Chinese South Western Oncology Group (No. CSWOG-CCET005).